Two hundred and seventy-seven consecutive patients with non-Hodgkin's lymphoma (n = 207), Hodgkin's disease (n = 27) and multiple myeloma (n = 43) were intensified from October 1989 until April 1997 and received unmanipulated PBPC transplants. Twentythree patients received a double intensification, out of a total of 300 PBPC transplantations analyzed. Conditioning regimens consisted of total body irradiation (TBI)-containing regimens (n = 141), BEAM (n = 104), highdose melphalan (n = 26), ICE (n = 23) or other regimens (n = 6). Eighty-four percent of the patients (119/142) evaluable for long-term hematological reconstitution beyond 180 days achieved normal trilineage blood counts. Abnormal hematological parameters were associated with low numbers of CD34 + cells re-infused and with prior exposure to fludarabine. The 100-day and long-term treatment-related mortality rates were 4% and 4%, respectively. Late complications and treatment-related toxicities were influenced by disease history, use of TBI and exposure to fludarabine. Patients older than 60 years did not have greater toxicities or more frequent treatment-related deaths. This analysis suggests that while leading to a limited morbidity and a low mortality rate, intensive chemotherapy with PBPC transplantation still remains a procedure leading to significant short-and long-term toxicities. Better recognition of the risk factors associated with these complications might allow a further decrease in their incidence.
patients with intensive chemotherapy followed by autologous hematopoietic progenitor cell support. This treatment option has been shown to be superior when compared with standard chemotherapy in patients with relapsing 3 or high risk 4, 5 non-Hodgkin's lymphoma, as well as in those with high risk multiple myeloma. 6 Furthermore, high-dose chemotherapy with autologous progenitor cell transplantation may bring some benefit in Hodgkin's disease at relapse, 7 and has been used in selected non-hematological malignancies. 8, 9 Over the past few years, mobilized peripheral blood progenitor cells (PBPC) have largely replaced autologous bone marrow transplantation as the predominant cell source, 10 mainly because it confers a significant advantage for hematopoietic reconstitution, [11] [12] [13] [14] and may be the unique source for hematopoietic rescue in cases with hypoplastic bone marrow. 15 Furthermore, PBPC transplants have been shown to result in less morbidity than bone marrow transplants, 11, 16 even though the toxic death rate in experienced centers is around 4 to 6%. [17] [18] [19] We describe 300 consecutive PBPC transplants performed in a single institution in patients with lymphoproliferative diseases. The goal of the study was to analyze the different factors affecting toxicity of this procedure and to assess precisely late morbidity and mortality related to intensive chemotherapy.
Materials and methods

Patients
From October 1989 until April 1997, 277 patients (Table 1) with lymphoproliferative disorders were treated at the Centre Hospitalier Lyon-Sud with intensive chemotherapy and unmanipulated PBPC transplantation. Patients were selected for intensive chemotherapy: (1) because they were refractory or they had relapsed after a first-line treatment for NHL or HD; (2) because they had NHL with two or three unfavorable prognosis criteria according to the International Prognosis Index at diagnosis; 20 or (3) because they suffered from stage 3 multiple myeloma. Other criteria for eligibility included an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 and evidence of adequate pulmonary, hepatic, renal and cardiac function.
Twenty-seven patients were treated twice with high-dose chemotherapy. Eight patients received a second transplant In case of double intensification, only the first PBPC transplantation was considered for characteristics before intensive therapy. The four patients with previous autologous bone marrow transplant were not considered for this analysis.
with PBPC after a relapse occurring more than 1 year after a first intensification (supported with bone marrow cells in four cases and with PBPC in four other cases), whereas 19 patients received two sequential PBPC transplants. These 300 PBPC transplants was analyzed for acute toxicity. Long-term complications, including delayed treatmentrelated death, were only assessed once for each patient.
Patients who received sequential intensification were evaluated after the second transplant while patients who received a second transplant after relapse were only considered after their first PBPC transplant (and excluded from this analysis if the first transplant was performed with marrow). In addition, the first 150 intensive treatments performed from October 1989 until March 1995 were compared for toxicity with the next 150 treatments performed in the last 2 years. Disease status was assessed at harvest by physical examination, chest X-ray and computerized tomography. Quantity of paraprotein on electrophoresis was assessed before harvest in multiple myeloma patients. Bone marrow analysis was performed in all patients at harvest except for those without previous bone marrow involvement who were responsive to their last therapy.
Mobilization regimen and collection of PBPC
Of the 277 patients, 266 were mobilized with chemotherapy followed by G-or GM-CSF and 11 patients with hematopoietic growth factors alone. Mobilization chemotherapy consisted of high-dose cyclophosphamide (3 to 6 g/m 2 ) in 131 patients, of cyclophosphamide 4.5 g/m 2 plus etoposide 450 mg/m 2 for 70 patients, and 65 patients were mobilized with standard chemotherapy, generally consisting of the last course of the induction regimen. Twenty-five patients required additional mobilization procedures because of inadequate quality of the first harvest. 21 Leukaphereses were performed as previously described. 22 
Measurement of progenitor cell content
The percentage of CD34 + cells in the apheresis product was determined using flow cytometry as previously described. 22 PBPC collections were performed daily to obtain at least 2 × 
CD34
+ cells/kg.
Conditioning chemotherapy
All patients were treated in a protected environment in individual rooms with high-efficiency particulate air filtration, with the exception of 14 who stayed in a standard specialized medical unit. One hundred and forty-one patients (47%) received a TBI-containing regimen, consisting of melphalan 140 mg/m 2 (day 1) with 10-12 Gy fractionated TBI (days 2-4) in 25 patients, of cyclophosphamide 120 mg/kg (days 1-2) and etoposide 900 mg/m 2 (days 1-3) combined with 10 Gy fractionated TBI (days 4-6) in 115 patients, or of carboplatin and melphalan plus 12 Gy fractionated TBI in one patient. One hundred and four patients (35%) received BEAM chemotherapy which consisted of BCNU 300 mg/m 2 (day 1), etoposide 800-1600 mg/m 2 plus aracytine 800-1600 mg/m (days 2-5) and melphalan 140 mg/m 2 (day 6). Twenty-six patients were treated with highdose melphalan (140 mg/m 2 in four and 200 mg/m 2 in 20 patients, respectively). The ICE regimen was administered to 23 patients and consisted of ifosfamide 12 g/m 2 (days 1-4), carboplatin 1500 mg/m 2 and etoposide 1500 mg/m 2 (days 1-3). Other regimens consisted of CBV (cyclophosphamide, BCNU, etoposide) in one patient, CBV plus melphalan (n = 1), in CBV-novantrone (n = 3) and carboplatin-busulfan-melphalan (n = 1). PBPC were reinfused 2 or 3 days after the last day of chemotherapy (BEAM/ melphalan or ICE regimen, respectively) or on the last day of irradiation when the regimen involved TBI.
Toxicity
Hematological toxicity was defined from the day of PBPC reinfusion (day 0). The time to an absolute neutrophil count (ANC) of greater than 0.5 × 10 9 /l was defined as the number of days from day 0 for the neutrophils to increase and to be stable for at least 3 days over these values, and the time to platelets over 20, 50 or 100 × 10 9 /l as the number of days from day 0 for platelets to be stable over these values without transfusion. Blood product transfusions and antimicrobial regimens were given according to usual institutional guidelines. 22 Only patients with continuing complete remission (CR) who did not receive either chemo-or immunotherapy were assessed for long-term hematological toxicity. If two intensifications were sequentially performed, long-term hematopoietic recovery was only assessed after the second treatment. Because all patients with incomplete red cell or leukocyte incomplete recovery also had abnormal platelet counts, long-term hematological reconstitution was first assessed in patients who did not achieve 150 × 10 9 /l platelets by day 180. We then analyzed the hematological outcome of this patient subgroup for full hematological recovery.
Non-hematological toxicities were evaluated according to the World Health Organization (WHO) grading. Only grade 3 or more toxicities were considered. Early infections were defined as infections occurring within the first 30 days after PBPC transplantation.
Late infections were defined as infectious events occurring after day 30 in patients who had reached an ANC of greater than 1.0 × 10 9 /l (therefore excluding graft failures). Treatment-related mortality was finally evaluated based on the number of patients who died within the 100 days following PBPC reinfusion because of high-dose treatmentrelated complications, and on the number of patients who died beyond this delay from complications that could be related to intensification. Risk factors for treatment-related mortality were assessed after excluding the patients with engraftment failure.
Response
Tumor assessment was evaluated at harvest and before conditioning, and response to intensive chemotherapy was then evaluated 3 months after transplant. CR was defined as the disappearance of disease from all sites including bone marrow. Partial remission (PR) was defined as a reduction of more than 50% of the two largest diameters of each measurable lesion, or as persistence of bone marrow infiltration as the only residual site of disease. Stable disease (SD) was defined as a reduction of less than 50% in these measures. Progressive disease (PD) was defined as the appearance of a new lesion or as an increase in size of any pre-existing lesions. With multiple myeloma, CR was defined as the absence of paraprotein on electrophoresis associated with fewer than 5% of plasma cells of normal morphology in the bone marrow, and PR as a decrease of 50% in paraprotein level and plasma cell infiltration in bone marrow.
Statistical analysis
Distributions of clinical characteristics and variables were compared using the chi-square test. Multivariate analyses were performed using logistic regression models. Patients who had not achieved a platelet count of 20 × 10 9 /l by day 180 were designated as 180+ in the median range while patients who died before engraftment were censored for hematological recovery on the date of death. Overall survival (OS) was defined as the time from reinfusion of PBPC to death or date of last visit. Freedom from progression (FFP) was defined as the time from reinfusion of PBPC to the time of disease progression. Survival distributions and risk of myelodysplasia or acute myeloid leukemia (MDS/AML) were estimated by the Kaplan-Meier productlimit method. 23 
Results
Early hematopoietic recovery
All patients were reinfused with PBPC, but six of them treated before January 1993 also received bone marrow. The median number of MNC reinfused was 3.52 × 10 8 /kg and the median number of CD34 + cells, available for 186 patients only, was 5.97 × 10 6 /kg. The median times to achieve an ANC Ͼ0.5 × 10 9 /l was 11 days (range 6-85) and all patients achieved an ANC Ͼ0.1 × 10 9 /l, but four died on days 13, 17, 40 and 85, respectively, without having achieved an ANC Ͼ0.5 × 10 9 /l. The median times to achieve an unsustained platelet count Ͼ20, 50 or 100 × 10 9 /l were respectively 10 (range 6-180+), 14 (range 7-180+) and 17 days (range 9-180+). Eleven patients did not achieve sustained neutrophil engraftment and six died within 100 days (three patients with sepsis, two patients from hemorrhage and one from pneumonitis) and five died later from various infections. Since the cause of death was then clearly related to engraftment failure, these patients were not further considered for any long-term toxicity.
Early non-hematological toxicity
Twenty-four percent of patients developed an infection of more than grade 3 during their hospital stay, from which three died (Table 2) . Cardiac, pulmonary, renal and hepatic toxicities occurred each in less than 5% of patients, but were lethal in three cases (Table 3) . Two other patients developed veno-occlusive disease that finally resolved. Only уgrade 3 toxicities have been reported in this Table. a Calculated on 263 patients only and not on the 300 PBPC transplantations. 
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Patient outcome
Three months after transplant, 167 patients were in CR and 53 in PR (overall response rate of 81%), while five patients had stable disease, 31 had progressed and 12 had died. Five patients were not evaluated at this time. With a median follow-up of 22 months (range 6-81), 189 patients were still alive (157 without progression), whereas 84 patients had died, 59 of them following relapse, 23 of treatmentrelated causes (two also in relapse), and two because of a second malignancy (both oesophageal carcinoma). The median time for freedom from progression (FFP) has not been reached and the projected median overall survival (OS) was 5.3 ± 1 years. A total of 23 patients experienced treatment-related mortality (Table 3) . Twelve patients (12/273; 4%) died within the first 100 days following transplantation: from sepsis (n = 5), hemorrhage (n = 3) pneumonitis (n = 1), cardiac failure (n = 1), veno-occlusive disease (n = 1) and multiple organ failure (n = 1). Eleven patients (11/273; 4%) died later of treatment-related complications, five from infections associated with failure of sustained hematopoietic recovery, and one from pneumonitis with a normal blood count. Finally, five patients died of MDS/AML. Two other patients developed MDS/AML but were still alive with a follow-up of 3.2 and 6.6 years, respectively. The crude incidence of secondary MDS/AML was then 3% (7/273), but the projected cumulative incidence was 13 ± 6% at 5 years.
Long-term hematological reconstitution
Blood counts were assessed 6 months after PBPC transplant in patients receiving only one transplant without engraftment failure who were in persistent CR without receiving any further antineoplastic treatment. Out of 145 patients meeting these criteria, 94 patients had normal blood counts with platelets over 150 × 10 9 /l. Of the 51 patients who had not achieved these counts, 25 had trilineage recovery later, 16 remained thrombocytopenic at 50 to 150 × 10 9 /l with a median follow-up of 23 months, and two patients never reached 50 × 10 9 /l platelets (one died 17 months after transplant following relapse and the other had only 21 × 10 9 /l platelets after a follow-up of 23 months). Five patients developed myelodysplasia or acute myeloid leukemia (MDS/AML) after a median of 2.5 years, without ever achieving complete hematopoietic recovery. Finally, two patients were lost to follow-up, and one died of pneumonitis without achieving a completely normal blood count. Thus, among the 142 patients evaluable for longterm hematological reconstitution, 119 (84%) finally had normal and sustained trilineage recovery.
Late infections
This analysis was performed on patients after a single transplant (n = 273) excluding patients with engraftment failure (n = 11, including one patient with two transplants) for a total of 263 patients at risk. Sixty-six patients (25%) developed a total of 68 late infections (after day 30). The most frequent (n = 34) were varicella zoster virus (VZV) infections, consisting of 32 herpes zoster and in two varicella infections, all without visceral dissemination. Other infections consisted of pneumonitis or obliterative bronchitis (n = 18), CMV or EBV (n = 5 and n = 2, respectively), bacterial septicemia (n = 2), tuberculosis (n = 2) and miscellaneous (n = 4).
Factors influencing hematopoietic recovery (Table 4)
Engraftment failure was associated with a longer duration (у6 months) of previous chemotherapy (P = 0.002) and PBPC transplantation performed after the first line of treatment (P = 0.009). As described in detail previously, 22 the number of CD34 + cells re-infused was the main factor affecting early hematopoietic recovery. Long-term hematological reconstitution appeared significantly influenced only by the dose of CD34 + cells reinfused (P = 0.0001) and by previous exposure to fludarabine (P = 0.01). Other parameters relating to age and disease, treatment history (line, number or duration of previous treatments, use of alkylating agents) or intensification (number of MNC or CFU-GM cells reinfused, conditioning regimen, number of intensification) were not associated with altered long-term hematopoietic reconstitution.
Factors influencing non-hematologic toxicity
Development of acute infections was only associated with the number of CD34
+ cells reinfused ( Table 4 ). The line of treatment seemed to significantly predict visceral toxicity. The onset of late infections appeared associated with use of TBI, exposure to fludarabine and number of prior treatments. Exposure to fludarabine and use of TBI were both significantly associated with the development of secondary MDS/AML. Of note, four of the 36 patients (11%) who received fludarabine and TBI developed secondary MDS/AML with a median onset of 2.7 years (range 2.1-3.1). However, only three (3%) of the 102 patients intensified with TBI, who never received fludarabine, developed MDS with a median onset of 4.4 years (range 2.5-5.7).
Finally, when excluding patients with engraftment failure, treatment-related mortality was significantly associated + cell counts were assessed. b Including one of the following grade у3 toxicity: hepatic, cardiac, renal or pulmonary (non-infectious). c Assessed with the log-rank test. d Cannot be computed with the log-rank test because only one event occurred in the CD34 + cell group. e Assessed only in patients without a history of double transplant (23 double PBPC transplantations and four patients with previous BM transplant) and in patients without graft failure (11 cases, including one patient with previous BM transplant); for long-term hematological reconstitution, only patients in complete remission without further therapy were considered.
with the use of fludarabine, TBI administration and line of treatment (Table 4) . When a stepwise regression analysis was performed to evaluate the relative weight of these three variables, only line of treatment (relative risk = 24.5; 95% confidence interval (2.08-290); P = 0.003) remained significant, while a trend was observed for use of fludarabine (RR = 4.12; 95% CI (0.97-17.6); P = 0.051) and administration of TBI (RR = 4.6; 95% CI (0.85-25.1); P = 0.059).
Of interest, age over 50 at transplant was not associated with significantly more toxicity (n = 124).
Decrease in toxicity over time
When the 150 patients treated in the last 2 years of this study were compared to patients treated in the first 4 years, the former appeared significantly older but were significantly less heavily pretreated (data not shown). As a result of these more favorable characteristics, lower numbers of treatment-related deaths were observed in the group of patients treated in the last 2 years compared to those treated earlier (3 vs 20, P = 0.0005). This difference reflected a drop both in early (3 vs 9) and late (0 vs 11) treatmentrelated mortality. However, this later result has still to be interpreted cautiously, since some events such as late infections or MDS/AML may not yet have occurred in the recently treated population.
Discussion
These data confirm that PBPC transplantation is now a safe procedure in most cases, usually allowing rapid hematopoietic recovery, but acute and late toxicities may still occur which are important to recognize.
As already reported, early hematopoietic recovery following PBPC transplantation is mostly influenced by the number of CD34
+ cells re-infused. 22, [24] [25] [26] We observed 11 patients who showed engraftment failure. All but one of them were intensified before June 1994, when the quality of the harvest was mainly assessed by MNC count and CFU-GM cultures, while none of the last 150 patients in whom CD34 + cell counts were monitored experienced early neutrophil engraftment failure. However, the ability of PBPC to provide and maintain long-term hematopoiesis has been questioned. 27, 28 In this study, besides the 11 early graft failures, we observed that 84% of patients evaluable for long-term hematological reconstitution experienced normal trilineage recovery but 18 patients remained thrombocytopenic, the thrombocytopenia being clinically significant in only two cases. The only significant parameters associated with incomplete long-term reconstitution were low CD34 + cell counts and exposure to fludarabine. The use of fludarabine has also been associated with a decreased CD34 + cell yield in PBPC harvests, 21 therefore suggesting that CD34 + cell count may constitute the principal determinant of longterm reconstitution. Previous studies also reported that the level of CD34 + cells reinfused had an influence on late engraftment, 29 but age, time to achieve short-term reconstitution and bone marrow involvement were also found to be significant. 30 However, even patients with normal trilineage recovery after PBPC transplantation may have long-term impairment of the hematopoietic system with marked reduction in bone marrow progenitors. 31 Impairment of immune recovery after PBPC transplantation has also been reported, but was not assessed in the current study. 16, 32 In this study, infectious events appeared to be the main non-hematological toxicity, when fever and digestive symptoms were excluded, and consisted mainly of bacteremia and pulmonary infections. Only low CD34
+ cell counts were found to significantly influence the occurrence of infections. Some authors have reported that the use of TBIcontaining conditioning regimens increased both early and late infections after autologous transplants. 33 In this analysis, use of TBI and exposure to fludarabine appeared to significantly increase the incidence of late, but not acute infections.
In this series, 3% of patients developed secondary MDS/AML, corresponding to a 5-year projected incidence 13 ± 6%. Others have reported a crude incidence between 2 and 8%, 7, [34] [35] [36] and a projected 5-year incidence as high as 15%. 35 TBI appeared to significantly augment the risk of secondary MDS, as reported by others. 34, 36 The significant role of TBI-containing conditioning regimens in treating poor prognosis lymphoproliferative diseases has been noted 37 but preliminary data have suggested that the outcome of low grade non-Hodgkin's lymphoma patients might not be influenced by the use of TBI. 38 Considering the toxicity profile of TBI and its unavoidable long-term toxicities, other studies will be needed to further compare therapeutic efficacy of different regimens for intensification. In the present analysis the other predictive factor for the occurrence of MDS/AML was previous exposure to fludarabine. Of concern, the delay in onset of MDS in the four patients who previously received fludarabine appeared shorter when compared to the onset of MDS in those who were never treated with this agent. Further studies are warranted to confirm these results given the increasing use of fludarabine in the treatment of hematological malignancies.
Some authors have described a worse outcome in older patients receiving autologous transplantation for hematological malignancies, but the large majority of patients included in these reports were transplanted with bone marrow. 39, 40 Others have shown that PBPC transplants were feasible with acceptable toxicity in selected patients over 60 years old. 41, 42 In the present study, age did not significantly influence early or long-term hematopoietic recovery, nonhematological toxicity, or treatment-related death, indicating that selected patients older than 60 with hematological malignancies should be considered for intensive therapy with PBPC transplantation.
Using PBPC rather than bone marrow has allowed a decrease in post-transplant morbidity, 11, 16 and some authors have described a tendency to reduced mortality. 14 In the current study, rates of transplant-related mortality observed within the first 100 days and long-term (4% and 4%, respectively) appear in accordance with the incidence reported by others. 7, [17] [18] [19] It is worth noting that when comparing the 150 early with the 150 later PBPC transplants, the 100-day treatment-related death rate decreased from 6% to 2%, probably reflecting an improvement in supportive care and better assessment of the harvest quality, but also selection of patients with a shorter disease history before high-dose therapy.
In conclusion, this study confirms that intensive chemotherapy with PBPC transplantation is now a safe procedure in most patients treated for lymphoproliferative malignancies. CD34
+ cell count appears to be the most important factor for early and long-term hematopoietic recovery. Exposure to fludarabine and use of TBI are associated with greater long-term toxicity. Finally, when intensive treatment with PBPC transplantation is under evaluation for the treatment of non-malignant diseases, 43 it should be noted that despite the improvement in supportive care, long-term treatment-related mortality of this procedure still remains significant.
